Efficacy of 5-Fluorouracil in the Treatment of Pterygium.
5 fluorouracil
5fu
efficacy
primary pterygium
pterygium
recurrent pterygium
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
12 Jan 2021
12 Jan 2021
Historique:
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Objective To determine the efficacy of 5-Fluorouracil (FU) in the treatment of pterygium. Methodology After meeting the inclusion criteria 101 patients were enrolled in this study. Informed consent and demographic information was taken from all the patients. Patients underwent ophthalmic clinical examination that included slit lamp examination to grade pterygium. Before starting 5-FU injections, all topical medication was stopped. After four weeks the effects of 5-FU and its efficacy was noted. The patients were reviewed again after six months to note any recurrence. All the collected data was entered and analyzed on Statistical Package for Social Sciences (SPSS) version 20 (IBM Corp., Armonk, NY). Results In our study the mean age of the patients was 37.74 ± 10.15 years, male to female ratio of the patients was 1.06:1. The primary type of pterygium was noted in 54 (53.5%) and recurrent was noted in 47 (46.5%) patients. The efficacy achieved in 88 (87.13%) patients, four had recurrence of pterygium and of 101 patients 26 underwent surgical excision. Conclusion The use of 5-FU is safe and effective for the treatment of pterygium and it can be implemented as a primary treatment especially in the hot temperate zone where it is very common and aggressive with high recurrence rate. 5-FU not only halts its progression but also reduces the size and vascularity thus decreasing the need for surgery and steroid use and preventing recurrence.
Identifiants
pubmed: 33489629
doi: 10.7759/cureus.12652
pmc: PMC7805499
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12652Informations de copyright
Copyright © 2021, Shah et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biomed Res Int. 2014;2014:658648
pubmed: 25165711
Clin Pharmacol Ther. 2013 Dec;94(6):640-5
pubmed: 23988873
Anticancer Res. 2007 Nov-Dec;27(6B):4135-41
pubmed: 18225584
Am J Pathol. 2011 Feb;178(2):817-27
pubmed: 21281814
Int J Ophthalmol. 2014 Jun 18;7(3):563-73
pubmed: 24967209
Arch Ophthalmol. 1995 Nov;113(11):1356-7
pubmed: 7487587
Arq Bras Oftalmol. 2009 Mar-Apr;72(2):169-73
pubmed: 19466323
Ophthalmology. 1998 May;105(5):901-4; discussion 904-5
pubmed: 9593395
Nature. 1957 Mar 30;179(4561):663-6
pubmed: 13418758
Pharmacogenomics. 2011 Sep;12(9):1321-36
pubmed: 21919607
Br J Ophthalmol. 2008 Jan;92(1):25-9
pubmed: 18055574
Saudi J Ophthalmol. 2013 Apr;27(2):107-11
pubmed: 24227970
J Pak Med Assoc. 2016 May;66(5):559-62
pubmed: 27183936
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Eye (Lond). 2013 Oct;27(10):1123-9
pubmed: 23807385
Cornea. 1995 Sep;14(5):473-84
pubmed: 8536460
Ophthalmology. 2009 Feb;116(2):175-84
pubmed: 19187822
Ophthalmology. 2006 Jul;113(7):1102-9
pubmed: 16730066